SAM
INDP icon

Strategy Asset Managers’s Indaptus Therapeutics INDP Stock Holding History

Strategy Asset Managers’s Portfolio INDP Stock Details INDP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-1,619
Closed -$24.9K – 245
2025
Q1 		$24.9K Hold
1,619
– – 0.01% 242
2024
Q4 		$38.2K Hold
1,619
– – 0.01% 243
2024
Q3 		$56.2K Hold
1,619
– – 0.01% 245
2024
Q2 		$86.6K Hold
1,619
– – 0.02% 242
2024
Q1 		$102K Hold
1,619
– – 0.02% 229
2023
Q4 		$79.8K Hold
1,619
– – 0.02% 226
2023
Q3 		$125K Hold
1,619
– – 0.03% 226
2023
Q2 		$86.6K Sell
1,619
-357
-18% -$20.8K 0.02% 242
2023
Q1 		$102K Hold
1,976
– – 0.03% 241
2022
Q4 		$80K Hold
1,976
– – 0.02% 242
2022
Q3 		$120K Buy
+1,976
New +$154K 0.03% 246

Other funds holding INDP

SS
SBI Securities Tokyo, Japan $3.65B AUM 41.88% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

Strategy Asset Managers's INDP Position: Q2 2025 in Review

Strategy Asset Managers sold out of Indaptus Therapeutics (INDP) in Q2 2025, closing a stake of 1,619 shares — an estimated $24.9K sold.

Strategy Asset Managers first reported a position in INDP in Q3 2022 and held it in 11 quarters. The position peaked at $125K in Q3 2023. 5 funds tracked by Wall St. Rank hold INDP as of Q2 2025.

  • Strategy Asset Managers reported no remaining Indaptus Therapeutics position as of Q2 2025 after selling out during the quarter.
  • Strategy Asset Managers sold 1,619 Indaptus Therapeutics shares in Q2 2025, an estimated $24.9K.
  • Strategy Asset Managers first reported a position in Indaptus Therapeutics in Q3 2022 and held it in 11 quarters.
  • Strategy Asset Managers's Indaptus Therapeutics position peaked at $125K in Q3 2023.
  • 5 funds tracked by Wall St. Rank held Indaptus Therapeutics as of Q2 2025.

Based on Strategy Asset Managers's 13F filing for Q2 2025, filed 7 Aug 2025.